In July 2022, the Company and its board of directors approved a strategic plan to align with its refocused pipeline on its next generation capsid assembly modulators (CAMs) and research programs and reduced its workforce by approximately 30%. The Company incurred cumulative restructuring charges of $1.1 million representing all costs to be incurred. These restructuring charges consisted solely of employee severance and related benefits, including $1.0 million in severance payments to executive officers impacted by the restructuring, $0.8 million in one-time termination severance payments and other employee-related costs associated with the restructuring and a reversal of $0.7 million

for previously recognized stock-based compensation expense related to forfeited awards based on the Company's policy of recognizing stock-based awards with graded vesting schedules using an accelerated attribution method on a straight-line basis over the requisite service period for each separately vesting portion of the award and to recognize forfeitures when they occur.

There were no restructuring charges incurred during the three and nine months ended September 30, 2023. The Company incurred $0.8 million in restructuring charges for the three months ended September 30, 2022, $0.7 million of which were included in research and development expenses and $0.1 million in general and administrative expenses. The Company incurred $1.8 million in restructuring charges for the nine months ended September 30, 2022, $1.3 million of which were included in research and development expenses and $0.5 million in general and administrative expenses.

A summary of accrued restructuring charges, included as a component of other accrued expenses on the Company's condensed consolidated balance sheet as of September 30, 2023, is as follows (in thousands):


Accrued balance as of December 31, 2022	$	599
Reductions for cash payments		(599	)
Accrued balance as of September 30, 2023	$	—